Tag Archives: announced

Traffic diversion plans announced for the PSL match | Instant News


Deputy Inspector General of Police (DIG) Javed Ali Mahar, head of the Karachi Traffic Police, on Saturday issued a traffic diversion plan for the Pakistan Super League (PSL) match.

The traffic police spokesman said that the remaining 2020 Pakistan Super League (PSL) matches were scheduled to be held on November 15 and 17 at the Karachi National Stadium, and the traffic police had prepared special traffic arrangements and diversion plans.

Closed roads & alternative routes

During the match, traffic will be diverted to the points mentioned below. Road users are asked to use alternative routes to avoid inconvenience.

Karsaz

Any type of traffic coming from Sharea Faisal is not allowed via Jalan Habib Ibrahim Rehmat ullah towards the Stadium (Jalan Sir Shah Suleman). This vehicle will be diverted to Drigh-Sharea Faisal Street, turn left on Jalan Rashid Minhas, Millennium Mall to NIPA. Likewise, from the Airport to Drig Road, turn right at Rashid Minhas Road, Millennium Mall to NIPA.

Chowrangi New Town

From University Road of the New Town turn, any type of Traffic is not allowed to continue on Stadium Road. Traffic will be diverted towards Chowrani Prison, Shaheed-e-Millat or direct to PP Chowrangi. People who come to Aga Khan Hospital, Liaquat National Hospital and residences will be allowed to come from the PS side of Kota Baru. Traffic police staff will be there to assist them.

Hassan Square Flyover

Traffic coming from No. Liaquatbad. 10, Gharibabad, are not permitted to use the Hassan Square Flyover to the National Stadium. All vehicles will be diverted towards the Hassan Square Flyover down the road towards University Road, to reach their destination.

Millennium Mall

Any kind of traffic coming from Rashid Minhas Street is not allowed via Dalmia to continue towards the National Stadium.

These vehicles will be diverted to NIPA, Askari-IV (Millennium Mall), Drigh Road to Sharea Faisal or Millennium Mall, NIPA to Safoora Chowrangi or NIPA to Gulshan Chowrangi to Sohrab Goth.

Traffic jam

No heavy vehicles are not permitted to proceed from Sohrab Goth to NIPA, Liaquatabad No. 10 to Hassan Squire, and PP Chowrangi to University Road.

To avoid inconvenience, please follow the traffic police instructions as mentioned above. Park your vehicle in the parking lot. Do not park your vehicle on highways or main roads.

In case of inconvenience, people can call the Rahnuma-1915 traffic police helpline, where traffic staff are available to guide and assist you. Additionally, they can follow the Traffic Police Social Media Accounts: WhatsApp at 0305-9266907, Radio Tune Sindh Police FM 88.6 and the Facebook page at www.facebook.com/karachitrafficpolice for the latest information.

Security plan

DIG Maqsood Ahmed, head of the Sindh police Security Division, issued a very straightforward security plan for the PSL match to be played in Karachi.

He said the Karachi police had prepared a comprehensive security plan with regard to the PSL match.

The plan was drawn up in a meeting attended by high-ranking police officers, soldiers and rangers along with all stakeholders. Then, army commandos and police conduct joint mock drills to deal with unwanted incidents.

About 5,000 Karachi police personnel, 1,538 Security Division personnel, including 1,038 SSU personnel, 1,800 traffic police personnel, and 500 Special Branch personnel, will carry out security duties alongside personnel from other law enforcement agencies at Karachi National Stadium. , Karachi airport, routes, hotels and other different areas, while snipers will also be deployed at sensitive points.

Furthermore, seven SSPs and 16 DSPS from the Security Division will also carry out their duties. A special command & control bus will also be stationed at the National Stadium to monitor law and order around the stadium.

In addition, a Special Weapons and Tactics (SWAT) team consisting of highly trained and well equipped commandos, including female commandos, will remain vigilant at SSU Headquarters as a quick response force to deal with any emergency situation.

After safety concerns, on November 15 and 17, the route around the National Stadium will be closed during the match schedule for transportation, and residents are advised to use an alternative route.

.



image source

PM announced Rs11 billion for Karachi but not released even Rs11: Mustafa Kamal – Pakistan | Instant News


Published in November 10, 2020 12:24

PM Imran himself created a constitutional crisis in the country, said Mustafa Kamal.

KARACHI (Berita Dunya) – Pak Sarzameen (PSP) Party chairman Syed Mustafa Kamal Tuesday said Prime Minister Imran Khan announced a Rs11 billion package for Karachi but the metropolitan city did not even receive Rs11.

The PSP head said Imran Khan was still not convinced he was the country’s prime minister. Pakistani Tehreek-e-Isaf (PTI) leaders behaved as if they were handling an election campaign, said Mustafa Kamal.

“PM Imran himself created a constitutional crisis in the country because he said he would not have a dialogue with the opposition.

“Dogs bite people from Karachi to Kashmore but there is no vaccine. Karachi has become the dirtiest city in the world with unemployment and the worst transportation system.

“People have lost their trust in all other parties. People from all over the country were brought in for the October 18 rallies but no public interest agenda was discussed at the meeting convened by eleven parties.

“The Karachi people are being treated not seriously and the drama cannot happen anywhere other than Pakistan.”

.



image source

Panasonic announces S 85mm f/1.8 L lens | Instant News


Panasonic announced the launch of a new S 85mm f/1.8 full-frame lens suitable for L-mount cameras. The design is compact and lightweight, with beautiful bokeh and clear details.


|
Panasonic S 85mm f/1.8 in Interchangeable lens

Matsushita Announced the launch of the new Lumix S 85mm f/1.8 fixed focus lens-a lens designed as a compact fixed focus lens with beautiful bokeh (with 9 aperture blades), which is weather-sealed and comparable to other lenses on the market Compared with the product, the price is quite competitive. It has been launched as part of a series of matching prime lenses and has been shown as part of Panasonic’s new L-mount lens roadmap. The LUMIX S 85mm F1.8 will be available at the end of November with a suggested retail price of £599.99 (Euro 679.99 in Ireland).

Panasonic launches new lightweight and compact LUMIX S 85mm F1.8 lens for its full-frame S-series cameras

From Panasonic: November 4, 2020 -Panasonic is pleased to introduce the new large-aperture medium and far fixed focus lens LUMIX S 85mm F1.8 (S-S85).

Panasonic LUMIXS S85 tilt

Based on the L-mount system used in the LUMIX S series of full-frame mirrorless cameras, the 85mm F1.8 is the first of four F1.8 large aperture lenses announced by Panasonic. The four F1.8 lenses have the same size and position of control parts to provide practical advantages. Since the diameter is the same, the same filter can also be used.

Composed of 9 elements in 8 groups, using 2 ED (ultra-low dispersion) lenses can effectively suppress axial chromatic aberration and chromatic aberration of magnification. Panasonic S series lenses pursue the beauty of bokeh, while LUMIX S 85mm F1.8 can provide smooth defocus gradation from the focus peak to adjacent areas of the image, and smooth circular bokeh from point light sources without vignetting . LUMIX S 85mm F1.8 also has a mechanism to suppress focus breathing and is also excellent in video recording performance. The filter is 67 mm in diameter and has a 9-blade circular aperture diaphragm.

LUMIX S 85mm F1.8 is light and compact (about 355g) and very flexible. Robust dust/splashproof* design can be used even under severe conditions of 10 degrees below zero.

Panasonic LUMIX S5 S S85 Top K
In addition to the planned four F1.8 large aperture lenses, a 70-300mm telephoto zoom lens is also being developed to further enhance the lineup of LUMIX S series lenses. Panasonic and the L-Mount System Alliance are committed to developing L-Mount lenses to further expand their product lineup to meet customer needs.

  • If the lens is in direct contact with dust and water, dust and splash agents cannot guarantee that damage will not occur.
  • L-Mount is a trademark or registered trademark of Leica Camera AG.
  • Design and specifications are subject to change without notice.

Panasonic S 85mm f/1.8 specifications

manufacturer Matsushita
general
Lens mount
lens
focal length 85 mm
Field of view 29°
Maximum aperture f / 1.8
Minimum aperture f/22
Filter size 67 mm
stable No
Equivalent to 35mm no data
Internal focus Yes
Maximum magnification 0.13 times
Focus
Minimum focus 80 cm
construction
blade 9
element 9
group 8
Package contents
Package contents Lens cap, rear lens cap, hood
Dimensions
weight 355 grams
height 82 mm

View complete product details

By making a Donate,buy Add member, Or shopping with one of our affiliate companies:
Amazon UK,
Amazon USA,
Amazon CA,
EBay UK,
Wicks

When using these links, you won’t spend any extra cost, but it does support the site and helps make ePHOTOzine free to use, thank you.

.



image source

About 40 thousand more people have contracted the corona virus in Brazil | Instant News


(MENAFN) Brazil’s health ministry announced on Friday that the combined tally of patients who tested positive for the new coronavirus had increased to 5,200,300 after 30,914 more cases were registered over the past 24 hours.

The minister’s statement also revealed that the national death toll also increased during the period reaching 153,214, with an additional 754 related fatalities.

He added that the largest share of all the country’s cases were reported from the Brazilian capital Sao Paulo as it reported a total of 1,057,240 cases and 37,870 deaths, while Rio de Janeiro was in second place with 289,440 cases and 19,654 deaths.

Brazil has the third largest caseload in the world, after the United States and India, and the second highest number of deaths from the disease, after the United States.

MENAFN1710202000450000ID1100972151

Legal Disclaimer: MENAFN provides information “as is” without warranty of any kind. We are not responsible or liable for the accuracy, content, images, videos, licenses, completeness, legality or reliability of the information contained in this article. If you have a complaint or copyright issue related to this article, please contact the provider above.

.



image source

Covid 19 coronavirus: All you need to know about today’s vaccine announcement | Instant News


The government today announced its first Covid-19 vaccine purchase agreement. What does it mean? Science reporter Jamie Morton explain.

What has been announced?

A deal that will provide New Zealand with about 1.5 million Covid-19 vaccines – or enough for 750,000 people.

But it is up to the vaccine makers – Pfizer and BioNTech – to successfully complete Phase III clinical trials, and pass regulatory approval here.

All is well, the vaccine could be shipped to New Zealand in the first quarter of next year, said Minister for Research, Science and Innovation Megan Woods.

“Pfizer says they are making good progress with the development of the Covid-19 vaccine,” he said.

“Depending on clinical and regulatory success, and provided the vaccine is approved for use here in New Zealand by Medsafe, it is likely that multiple doses will be available to us in the first part of 2021.”

What is the vaccine?

Global drug giant Pfizer and German biotechnology company BioNTech are behind a group of candidates – BNT162b2 – who are among the pioneers in the worldwide vaccine race.

Research so far has shown that this virus boosts antibody and T cell responses to SARS-CoV-2, the virus that causes Covid-19.

T-cells are white blood cells that can attack cells infected with the SARS-CoV-2 virus, while antibodies are able to neutralize the virus so that they cannot infect cells when they are first infected.

Overall, you have a strong shield against the coronavirus.

As an RNA vaccine, this vaccine works by bringing genetic material into cells, before being encoded for specific proteins from the virus.

As of this week, the vaccine is in its third and final Phase III trial at more than 120 locations around the world, with 28,000 people having been given a second dose.

This month, the two companies launched rolling submissions to the European Medicines Agency, while Health Canada has begun a real-time review of its candidates.

Is this the only vaccine we can use?

Professor Helen Petousis-Harris, University of Auckland vaccination specialist, said today’s announcement marks the first – and not the last, purchase agreement.

“There are still others on the table too,” he said.

Focus: How to stop the spread of the corona virus. Video / AP / Mark Mitchell

Australia, for example, has signed an agreement to mass-produce the University of Oxford and the AstraZeneca virus vector vaccine, ChAdOx1-S, also in Phase III trials.

It was shown to trigger a T cell response within 14 days of vaccination – and an antibody response within 28 days.

Like the influenza injections we are more used to, this is a viral vector vaccine, and uses a chunk of the pathogen to effectively stimulate an immune response against it.

Petousis-Harris said another pioneer was the LNP-encapsulated mRNA vaccine developed by the US National Institute of Allergy and Infectious Diseases and Massachusetts-based Moderna.

This month, eight groups received 17 vaccines in Phase III.

It is widely expected that the first vaccine will start rolling out at the end of the second quarter, or early third quarter, of 2021.

“So we hope it will be the middle of next year where we really start to see a vaccine available,” he said.

“But [the Pfizer-BioNTech candidate] potentially arriving a little earlier than that. “

How does this fit into New Zealand’s strategy?

The government says this complements other parts of our broader and recently launched vaccine strategy, such as the global Covax Facility which can provide for up to 50 percent of our population’s needs.

Prime Minister Jacinda Ardern visited the Malaghan Medical Research Institute in Wellington, which is involved in a local consortium working on locally made vaccines.  Photo / Getty Images
Prime Minister Jacinda Ardern visited the Malaghan Medical Research Institute in Wellington, which is involved in a local consortium working on locally made vaccines. Photo / Getty Images

It’s allocating hundreds of millions of dollars – won’t reveal exactly how much, for commercial reasons – to take the Kiwis and our Pacific neighbors as far as possible.

“The primary objective of our portfolio approach is to ensure we have flexibility and choice when it comes to securing the right vaccine for New Zealand and our Pacific neighbors,” said Woods.

The task force executing the strategy is now negotiating with other pharmaceutical companies, with further announcements expected next month.

Woods said “good progress” was being made on the deal, and having additional deals would ensure enough vaccines were available for the entire country.

There are concerns at a high level over New Zealand’s gaining early access.

One recently released Cabinet paper since August indicated that the Government is concerned that New Zealand’s COVID-19-free status and good health could mean it would not be prioritized if global priorities and allocations were simply left to needs assessments.

It recommends that New Zealand needs to provide “significant resources early on to help secure access to vaccines”.

Having a series of advance purchase agreements means potential access to a number of vaccine candidates, but it does not guarantee access to vaccines, as “it is likely that the majority of candidates considered will not be viable”.

Such prepayments cannot be recovered once they have been paid.

Determining the cost of the upfront agreement would be difficult, money had to be allocated to get started, the document said.

It is expected that early delivery of the vaccine costs between $ 75 and $ 150 per dose when slower delivery can cost less than $ 15.

So, who might get the vaccine first?

The call has yet to be made, but the Ministry of Health is working on what the immunization program should look like.

“A number of factors will influence who will receive what vaccine and when, such as data on trials of the suitability of each vaccine for a particular age group,” said Health Minister Chris Hipkins.

“We have set aside $ 66.3 million for medical supplies and infrastructure to ensure New Zealand is ready to launch the Covid-19 Immunization Program as soon as we have a safe and effective vaccine.

“Most of this investment will finance supplies sufficient to support the countries of New Zealand and the Pacific; supplies such as PPE, syringes, syringes and swabs, and refrigerators to store vaccines.”

What about local vaccine production?

The Covid-19 Vaccine Company led by Dr Robert Feldman aims to complete the first human trials of a new vaccine by the end of next year, which will cost about $ 8 million.  Photo / Provided
The Covid-19 Vaccine Company led by Dr Robert Feldman aims to complete the first human trials of a new vaccine by the end of next year, which will cost about $ 8 million. Photo / Provided

It happened too.

About $ 3 million in Government funding will go to Kiwi biotech company Biocell to upgrade its facilities so that it can launch 100 million doses.

Other Kiwi consortiums have been exploring potential candidates of their own – such as the inactivated vaccine approach led by Professor Miguel Quiñones-Mateu of the University of Otago, and a recombinant spike protein vaccine under development at the University of Victoria’s Dr Davide Comoletti laboratory – over the past few years. month.

And a local company has secured $ 3.3 million in private funding to go ahead with a Covid-19 vaccine made with Kiwi technology.

The Covid-19 Vaccine Corporation (CVC), which was founded in May, has collaborated with the University of Auckland, Callaghan Innovation, and the research institute Scion, in an effort to independently develop a local coronavirus agent.

The company aims to complete its first human trials of the new vaccine by the end of next year, at a cost of about $ 8 million.

– Additional reporting – RNZ

.



image source